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Abstract: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor 
blockers (ARBs) have shown cardioprotective and renoprotective properties. These agents 
are recommended as first-line therapy for the treatment of hypertension and the reduction of 
cardiovascular risk. Early studies pointed to the cardioprotective and renoprotective effects of 
ARBs in high-risk patients. The ONgoing Telmisartan Alone and in combination with Ramipril 
Global Endpoint Trial (ONTARGET) established the clinical equivalence of the cardioprotective 
and renoprotective effects of telmisartan and ramipril, but did not find an added benefit of the 
combination over ramipril alone. Similar findings were observed in the Telmisartan Randomized 
AssessmeNt Study in aCE INtolerant subjects with cardiovascular Disease (TRANSCEND) trial 
conducted in ACEI-intolerant patients. In ONTARGET, telmisartan had a better tolerability 
profile with similar renoprotective properties compared with ramipril, suggesting a potential 
clinical benefit over ramipril. The recently completed Olmesartan Reducing Incidence of 
Endstage Renal Disease in Diabetic Nephropathy Trial (ORIENT) and Olmesartan and 
Calcium Antagonists Randomized (OSCAR) studies will further define the role of ARBs in 
cardioprotection and renoprotection for high-risk patients.
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Introduction
Renin-angiotensin-aldosterone system (RAAS) blockade is a cornerstone of 
antihypertensive therapy in high-risk patients.1,2 Blockade of the RAAS reduces the 
risk of cardiovascular events and stroke in addition to providing renal protection.2,3 
Angiotensin receptor blockers (ARBs) are among the agents recommended as first-line 
therapy for treatment of hypertension and reduction of cardiovascular risk.1,2
Prior to the ONgoing Telmisartan Alone and in combination with Ramipril Global 
Endpoint Trial (ONTARGET), the clinical relevance of the cardioprotective and 
renoprotective effects of ARBs, angiotensin-converting enzyme inhibitors (ACEIs), 
or their combination was largely unknown. ONTARGET, which evaluated 25,620 
high-risk patients, provided a solid database to determine the benefits and risks of 
ARB and ACEI monotherapies as well as of combination therapy.4,5 This review article 
reassesses the role of ARBs in providing cardiovascular protection and the clinical 
implications of ONTARGET and similar trials.
RAAS in pathogenesis of cardiovascular  
and renal disease
The RAAS plays an important role in the pathophysiology of cardiovascular and 
renal disease.6,7 Its effects on the cardiovascular system include alterations in vascular Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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reactivity, endothelial function, fibrosis, tissue remodeling, 
inflammation, and oxidative stress.6–8 In addition, renal 
disease (eg, microalbuminuria) is associated with endothelial 
dysfunction, accelerated atherosclerosis, and proteinuria, 
as well as with increased risk of cardiovascular morbidity, 
end-organ damage, and death.9–11
Apart from lowering blood pressure, blockade of the RAAS 
may provide independent effects on end-organ protection.12 
Treatment with ACEIs and ARBs has demonstrated 
cardiorenal protective properties with favorable effects on 
blood pressure, renal hemodynamics, and proteinuria.13 
For example, agents that block the RAAS pathway attenuate 
intraglomerular pressure and improve endothelial function in 
resistant arterioles.10 Due to the phenomenon of ACE escape 
and complementary mechanisms of action, dual blockade 
with an ACEI and an ARB has been hypothesized to provide 
greater RAAS inhibition and, in turn, greater cardiorenal 
benefits.12,13
Cardiovascular protection  
with ARBs
The cardioprotective effects of ARBs were evident with the 
first ARB, losartan, as shown in a key pivotal trial, the Losartan 
Intervention For Endpoint Reduction (LIFE) study.14 The 
LIFE study was conducted to determine whether losartan was 
more effective than atenolol, a β-blocker, for the reduction 
of cardiovascular mortality and morbidity in hypertensive 
patients. This study was pivotal in establishing the role of 
angiotensin II blockade in cardiovascular protection. Losartan 
was better than atenolol in reducing the primary endpoint of 
cardiovascular death, stroke, or myocardial infarction by 14.6% 
(P = 0.009), and losartan was associated with a 25% lower 
incidence of new-onset diabetes, a significant cardiovascular 
risk factor. The cardiovascular protective effects were even 
more impressive in a subanalysis of 1195 diabetic patients 
enrolled in the LIFE study.15 This analysis established the 
efficacy of an ARB over that of a β-blocker in diabetic patients 
for cardiovascular protection, with a relative risk of 0.76 
for the primary endpoint of cardiovascular death, stroke, or 
myocardial infarction, in favor of losartan (P = 0.031).
This cardiovascular protective effect was shown in 
even higher risk patients in the Morbidity and Mortality 
After Stroke, Eprosartan Compared With Nitrendipine for 
Secondary Prevention (MOSES) study. The MOSES study 
was the first to demonstrate superiority of an ARB over 
a calcium antagonist for secondary stroke prevention.16 
The ARB, eprosartan, was shown to be superior to nitrendipine 
for the secondary prevention of morbidity and mortality after 
stroke in 1352 evaluable high-risk hypertensive patients with 
a history of a cerebral event within the previous 24 months, 
while having comparable reductions in blood pressure. 
The composite endpoint of mortality and all cardiovascular 
and cerebrovascular events, including recurrent events, was 
lower in patients treated with eprosartan versus nitrendipine 
(13.3 versus 16.7/100 patient-years; P = 0.014).
It has become clear in the last two decades that effective 
blockade of the RAAS confers important benefits in patients 
at high risk for cardiovascular disease. Earlier, ACE 
inhibitors were shown to confer target organ protection in 
patients with hypertension and diabetes; more recently, ARBs 
in large clinical trials have been shown to reduce the risk of 
cardiovascular, renal, and neurological complications.
ONTARGET resolved the question regarding the 
effectiveness of an ARB compared with an ACEI in 
high-risk patients with cardiovascular disease or diabetes 
mellitus without heart failure,17 although there continues 
to be confusion over the clinical implications of these 
findings. In ONTARGET, telmisartan was shown to be 
equivalent to ramipril in the incidence of primary outcome 
of death from cardiovascular causes, myocardial infarction, 
stroke, and hospitalization for heart failure (Figure 1).17 To 
underscore their similarities, the primary outcome occurred 
in 16.5%, 16.7%, and 16.3% of patients receiving ramipril 
alone, telmisartan alone, or their combination, respectively. 
The secondary outcome in ONTARGET, death from 
cardiovascular causes, myocardial infarction, or stroke, 
occurred in 14.1%, 13.9%, and 14.1% of patients receiving 
ramipril alone, telmisartan alone, or their combination, 
respectively. The relative risk ratio was 1.01 for the primary 
outcome and 0.99 for the secondary outcome with telmisartan 
versus ramipril, suggesting similarities in the degree of 
Primary composite outcome
Relative risk
(95% confidence interval) P value
0.8 0.9 1.0 1.1
Telmisartan better Ramipril better
1.2
0.003
<0.001 Main secondary outcome
Figure  1  Comparison  of  telmisartan  and  ramipril  for  the  relative  risk  of  the 
primary and secondary outcomes of ONTARGeT (ONgoing Telmisartan Alone 
and in combination with Ramipril Global endpoint Trial). The primary composite 
outcome was death from cardiovascular causes, myocardial infarction, stroke, or 
hospitalization  for  heart  failure.  The  main  secondary  outcome  was  death  from 
cardiovascular  causes,  myocardial  infarction,  or  stroke.  The  P  value  is  for  the 
comparison with the noninferiority margins. 
Copyright © 2008. Reproduced with permission from ONTARGeT investigators; 
Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk 
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cardioprotection offered by these agents individually and in 
combination over ramipril alone.17
Furthermore, data from ONTARGET do not support 
the use of the combination of an ARB plus an ACEI.17 The 
relative risk ratios of combination therapy compared with 
ramipril were 1.00 for the primary outcome and 0.99 for the 
secondary outcome. Blood pressure reductions were greatest 
in the combination therapy group, with an average reduction 
at six weeks of 9.8/6.3 mmHg compared with 6.4/4.3 mmHg 
for ramipril alone and 7.4/5.0 mmHg for telmisartan alone. 
However, no correlation of risk reduction was demonstrated 
in ONTARGET despite lower blood pressure in the 
combination group. Combination therapy was also associated 
with a higher incidence of adverse events.
Similar to ONTARGET, the Telmisartan Randomized 
AssessmeNt Study in aCE INtolerant subjects with cardio-
vascular Disease (TRANSCEND) trial was conducted with 
a population of patients intolerant to ACEIs with established 
coronary artery, peripheral vascular, or cerebrovascular 
  disease, or diabetes with end-organ damage.18 TRANSCEND 
showed a statistically significant benefit of telmisartan versus 
placebo for the secondary endpoint of cardiovascular death, 
myocardial infarction, and stroke (hazard ratio [HR] 0.87; 
P = 0.048).18 Compared with placebo, telmisartan was also 
associated with fewer cases of left ventricular hypertrophy 
and cardiovascular-related hospitalizations.
Another recently completed study, the Olmesartan and 
Calcium Antagonists Randomized (OSCAR) study, compared 
olmesartan (an ARB) alone with the combination of olmesartan 
and a calcium channel blocker in elderly high-risk Japanese 
patients with hypertension.19 Primary endpoints include the 
composite of fatal and nonfatal cardiovascular events, and 
death from any cause. Data from this study will provide further 
insight into the role of ARBs and combination therapy.
It remains to be shown whether there are some patient 
subgroups, such as those with diabetes and proteinuria, 
who may benefit from dual inhibition of RAAS. For now, 
in uncomplicated hypertension, dual blockade of RAAS is 
not indicated.
Long-term ARB tolerability  
and renoprotection
Early clinical trials suggested the efficacy of ARBs in the 
prevention of progression of nephropathy in diabetic patients. 
For example, the Irbesartan in Patients with Type 2 Diabetes 
and Microalbuminuria (IRMA) study demonstrated that at 
an optimal dose of 300 mg, irbesartan reduced the rate of 
progression to clinical albuminuria (HR 0.30; P , 0.001) and 
restored normoalbuminuria in a significant proportion of 590 
patients with hypertension and type 2 diabetes.20 Similarly, 
the Irbesartan Diabetic Nephropathy Trial (IDNT) was 
conducted to determine whether an ARB or a calcium channel 
antagonist would provide protection against advancing 
nephropathy in 1715 hypertensive patients with type 2 
diabetes beyond that of hypertension control.21 Compared 
with placebo and amlodipine, irbesartan had a 20% (P = 0.02) 
and 23% (P = 0.006) lower risk of a doubling of the baseline 
serum creatinine concentration, development of end-stage 
renal disease, or death from any cause.
ONTARGET showed a better tolerability profile of telmis-
artan versus ramipril, with fewer cases of angioedema (relative 
risk [RR] 0.4; P , 0.01) and cough (RR 0.26; P , 0.001) but a 
higher rate of hypotensive symptoms (RR 1.54; P , 0.001).17 
These data are consistent with those from previous studies, 
including a systematic review of 61 clinical trials.22 A meta-
analysis of randomized, controlled trials revealed cough rates 
of 9.9% in ACEI-treated patients compared with 3.2% in 
ARB-treated patients.22 Lower rates were observed in cohort 
studies, but the cough rate was consistently lower in ARB-
treated patients.22 In three studies reporting angioedema, all 
reported cases occurred in patients receiving an ACEI.22
Analysis of renal outcomes in ONTARGET showed 
equivalence between telmisartan and ramipril for effects on 
kidney function, including the primary renal outcomes of 
dialysis, doubling of serum creatinine, and death (Figure 2).23 
ONTARGET demonstrated that combination treatment with 
telmisartan and ramipril reduced albuminuria compared 
with ramipril (HR 0.88; P = 0.003) but was associated with 
increased risk of renal impairment and acute dialysis in high-
risk patients with diabetes and vascular diseases.23 Compared 
with ramipril alone, the combination of telmisartan and 
ramipril resulted in a higher incidence of renal dysfunction, 
doubling of serum creatinine, need for dialysis, and incidence 
of hyperkalemia.17,23
Similarly, during the TRANSCEND study, treatment 
with telmisartan was well tolerated.18 Fewer patients 
discontinued treatment with telmisartan than with placebo, 
despite more patients experiencing mild hypotensive 
symptoms.18 A recent analysis of renal outcomes for this 
study demonstrated that telmisartan was similar to placebo 
in renal outcomes, including the composite of doubling of 
serum creatinine and dialysis, and did not offer any significant 
renoprotective benefits.24 Telmisartan was shown to increase 
the incidence of the composite outcome in patients with no Vascular Health and Risk Management 2011:7 submit your manuscript | www.dovepress.com
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microalbuminuria or an estimated glomerular filtration rate 
(eGFR) of $60 mL/min/1.73 m2. However, this outcome 
was reduced in patients receiving telmisartan who had 
microalbuminuria or an eGFR , 60 mL/min/1.73 m2.24
The recently completed Olmesartan Reducing Incidence 
of Endstage Renal Disease in Diabetic Nephropathy Trial 
(ORIENT), a randomized, double-blind, placebo-controlled 
Phase III study, examined the effects of olmesartan on the rate 
of progression of diabetic nephropathy. Participants included 
patients in Japan and Hong Kong, aged 30 to 70 years, with 
type 2 diabetes mellitus.25,26 In this study, 577 patients were 
randomized to receive olmesartan 10–40 mg or placebo. The 
primary efficacy measure was a composite of the time to first 
occurrence of doubling of serum creatinine, end-stage renal 
disease, or death. Secondary efficacy endpoints included a 
composite of the time to first occurrence of a cerebrovascular/
cardiovascular event, change in proteinuria, and change in renal 
function calculated by the slope of the reciprocal of serum 
creatinine against time. Patients receiving an ACEI prior to 
enrollment were allowed to continue taking the same dose of 
the ACEI, with 72% of enrolled patients receiving combination 
therapy with an ACEI and olmesartan, and a median follow-up 
of three years.25 Results of ORIENT are not yet published.
Conclusion
Data from ONTARGET and TRANSCEND establish that 
telmisartan is as effective as ramipril. A growing body of 
evidence demonstrating the effectiveness and long-term 
cardiorenal protective properties of ARBs indicate that ARBs 
may be used successfully and with potentially greater clinical 
benefit compared with ACEIs. Additionally, the evidence 
suggests that each ARB may have unique properties that 
go beyond the established “class effect”. However, further 
investigation is needed to clarify these findings. ONTARGET 
data demonstrate that combination therapy with an ARB and 
an ACEI does not provide an additive benefit and, therefore, 
should not be used routinely in clinical practice, particularly 
in high-risk and elderly patients.
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Figure 2 Comparison of telmisartan and ramipril for the relative risk of the primary renal outcomes of dialysis, doubling of serum creatinine, and death in subgroups of 
ONTARGeT (ONgoing Telmisartan Alone and in combination with Ramipril Global endpoint Trial) patients. 
Reprinted from The Lancet, with permission from elsevier. Mann JF, Schmieder Re, McQueen MJ, et al; TRANSCeND (Telmisartan Randomised Assessment Study in ACe 
intolerant Subjects with Cardiovascular Disease) investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGeT study): A 
multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–553.23
Abbreviation: eGFR, estimated glomerular filtration rate.Vascular Health and Risk Management
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